Lexington, MA's Inotek Pharmaceuticals has pulled down a $21 million round to advance its lead product, designed to ease in-eye pressure for glaucoma patients. Inotek's eye drop, dubbed trabodenoson, works in tandem with glaucoma therapy latanoprost to increase fluid outflow in the eye's trabecular meshwork, and the cash will carry Inotek through a Phase II study of the duo, the company said. More